Substance / Medication

Mechlorethamine hydrochloride

Overview

Active Ingredient
mechlorethamine
RxNorm CUI
6674

Indications

VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

Labeler: Helsinn Therapeutics (U.S.), Inc.Updated: 2024-11-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

The use of VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

13
Total Trials
4
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.
Moritz Rose K C, Huynh Julia, Poch Gabriela et al. · J Dtsch Dermatol Ges · 2025
PMID: 39817814Meta-AnalysisFull text (PMC)
Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
Goyal Amrita, O'Leary Daniel, Foss Francine · Bone Marrow Transplant · 2024
PMID: 37853164Meta-Analysis
Early Organ Metastasis in Granulomatous Mycosis Fungoides: A Systematic Review.
Motamedi Melika, Xiao Maggie Z X, Deschenes Jean et al. · Dermatology · 2024
PMID: 38422999Meta-Analysis
Woringer-Kolopp disease (localized pagetoid reticulosis): a systematic review.
Osto Muhammad, Afify Omar, Musa Arif et al. · Int J Dermatol · 2023
PMID: 35485962Meta-Analysis
Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri Abdulhadi, Smith Jeffrey S, Larocca Cecilia · J Am Acad Dermatol · 2023
PMID: 36481378Meta-Analysis
Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review.
Schaefer Lauren, Comfere Nneka, Sokumbi Olayemi · Am J Clin Dermatol · 2023
PMID: 36627479Meta-Analysis
Topical chlormethine gel in the treatment of mycosis fungoides: A single-center real-life experience and systematic review of the literature.
Laghi Alessandro, Franceschini Chiara, Mandel Victor Desmond et al. · Dermatol Ther · 2022
PMID: 35778940Meta-Analysis
Short-term efficacy and safety of total skin electron beam therapy in mycosis fungoides: Systematic review and meta-analysis.
Grandi Vieri, Simontacchi Gabriele, Grassi Tommaso et al. · Dermatol Ther · 2022
PMID: 36124354Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Chlormethine hydrochloride (substance)
SNOMED CT
387071000
UMLS CUI
C0025033
RxNorm CUI
6674
Labeler
Helsinn Therapeutics (U.S.), Inc.

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
13
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.